Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
Anti-obesity medication
Bariatric
Roux-en-Y gastric bypass
Sleeve gastrectomy
Weight loss
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
received:
08
09
2023
accepted:
14
03
2024
revised:
14
03
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
A significant proportion of patients experience insufficient weight loss or weight regain after bariatric surgery. There is a paucity of literature describing anti-obesity medication (AOM) use following bariatric surgery. We sought to identify prevalence and trends of AOM use following bariatric surgery. We utilized the IBM Explorys® database to identify all adults with prior bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy). Those prescribed AOMs (semaglutide, liraglutide, topiramate, phentermine/topiramate, naltrexone/bupropion, orlistat) within 5 years of surgery were further identified. Data was analyzed to characterize AOM utilization among different age, demographic, and comorbid populations. A total of 59,160 adults with prior bariatric surgery were included. Among AOMs studies, prevalence of use was highest for topiramate (8%), followed by liraglutide (2.9%), phentermine/topiramate (1.03%), naltrexone/bupropion (0.95%) semaglutide (0.52%), and orlistat (0.17%). Age distribution varied, with the highest utilization among those age 35-39 years for topiramate, 40-44 years for phentermine/topiramate and naltrexone/bupropion, 45-49 years for semaglutide, and 65-69 years for liraglutide and orlistat. African American race was associated with higher utilization across all AOMs. Among comorbidities, hypertension, hyperlipidemia, and diabetes mellitus were most associated with AOM use. Despite a relatively high incidence of weight regain, AOMs are underutilized following bariatric surgery. It is imperative that barriers to their use be addressed and that AOMs be considered earlier and more frequently in patients with insufficient weight loss or weight regain after bariatric surgery.
Identifiants
pubmed: 38512645
doi: 10.1007/s11695-024-07181-w
pii: 10.1007/s11695-024-07181-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
World Health Organization. Newsroom. Obesity and overweight. https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight . Accessed 24 Dec 2023
Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–50. https://doi.org/10.1056/NEJMsa1909301 .
doi: 10.1056/NEJMsa1909301
pubmed: 31851800
Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files—development of files and prevalence estimates for selected health outcomes. In: National Health Statistics Reports; no 158. Hyattsville, MD: National Center for Health Statistics; 2021. https://doi.org/10.15620/cdc:106273 .
doi: 10.15620/cdc:106273
Moyer VA, Force USPST. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(5):373–8. https://doi.org/10.7326/0003-4819-157-5-201209040-00475 .
doi: 10.7326/0003-4819-157-5-201209040-00475
pubmed: 22733087
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. Oct 13 2004;292(14):1724-1737. https://doi.org/10.1001/jama.292.14.1724
Clapp B, Ponce J, DeMaria E, et al. American Society for Metabolic and Bariatric Surgery 2020 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2022;18(9):1134–40. https://doi.org/10.1016/j.soard.2022.06.284 .
doi: 10.1016/j.soard.2022.06.284
pubmed: 35970741
Crémieux PY, Ledoux S, Clerici C, et al. The impact of bariatric surgery on comorbidities and medication use among obese patients. Obes Surg. 2010;20(7):861–70. https://doi.org/10.1007/s11695-010-0163-6 .
doi: 10.1007/s11695-010-0163-6
pubmed: 20440579
Sundbom M, Hedberg J, Marsk R, et al. Substantial decrease in comorbidity 5 years after gastric bypass: a population-based study from the Scandinavian Obesity Surgery Registry. Ann Surg. 2017;265(6):1166–71. https://doi.org/10.1097/SLA.0000000000001920 .
doi: 10.1097/SLA.0000000000001920
pubmed: 27429019
Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34. https://doi.org/10.1111/joim.12012 .
doi: 10.1111/joim.12012
pubmed: 23163728
El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review. Obes Surg. 2021;31(4):1755–66. https://doi.org/10.1007/s11695-020-05160-5 .
doi: 10.1007/s11695-020-05160-5
pubmed: 33555451
pmcid: 8012333
Karmali S, Brar B, Shi X, et al. Weight recidivism post-bariatric surgery: a systematic review. Obes Surg. 2013;23(11):1922–33. https://doi.org/10.1007/s11695-013-1070-4 .
doi: 10.1007/s11695-013-1070-4
pubmed: 23996349
DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010;6(3):249–53. https://doi.org/10.1016/j.soard.2009.09.019 .
doi: 10.1016/j.soard.2009.09.019
pubmed: 20510288
Laurino Neto RM, Herbella FA, Tauil RM, et al. Comorbidities remission after Roux-en-Y Gastric Bypass for morbid obesity is sustained in a long-term follow-up and correlates with weight regain. Obes Surg. 2012;22(10):1580–5. https://doi.org/10.1007/s11695-012-0731-z .
doi: 10.1007/s11695-012-0731-z
pubmed: 22907795
Athanasiadis DI, Martin A, Kapsampelis P, et al. Factors associated with weight regain post-bariatric surgery: a systematic review. Surg Endosc. 2021;35(8):4069–84. https://doi.org/10.1007/s00464-021-08329-w .
doi: 10.1007/s00464-021-08329-w
pubmed: 33650001
Bastos EC, Barbosa EM, Soriano GM, et al. Determinants of weight regain after bariatric surgery. Arq Bras Cir Dig. 2013;26(Suppl 1):26–32. https://doi.org/10.1590/s0102-67202013000600007 .
doi: 10.1590/s0102-67202013000600007
pubmed: 24463895
Runge TM, Jirapinyo P, Chan WW, et al. Dysphagia predicts greater weight regain after Roux-en-Y gastric bypass: a longitudinal case-matched study. Surg Obes Relat Dis. 2019;15(12):2045–51. https://doi.org/10.1016/j.soard.2019.06.041 .
doi: 10.1016/j.soard.2019.06.041
pubmed: 31931976
Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952–72. https://doi.org/10.1016/j.soard.2014.02.014 .
doi: 10.1016/j.soard.2014.02.014
pubmed: 24776071
Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diab Endocrinol. 2018;6(3):237–48. https://doi.org/10.1016/S2213-8587(17)30236-X .
doi: 10.1016/S2213-8587(17)30236-X
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86. https://doi.org/10.1001/jama.2013.281361 .
doi: 10.1001/jama.2013.281361
pubmed: 24231879
pmcid: 3928674
Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500. https://doi.org/10.1016/j.soard.2016.10.018 .
doi: 10.1016/j.soard.2016.10.018
pubmed: 27986587
Altman DG. Practical Statistics for Medical Research. Boca Raton: CRC Press; 1990.
doi: 10.1201/9780429258589
Sheppard CE, Lester EL, Chuck AW, Birch DW, Karmali S, de Gara CJ. The economic impact of weight regain. Gastroenterol Res Pract. 2013;2013:379564. https://doi.org/10.1155/2013/379564 .
doi: 10.1155/2013/379564
pubmed: 24454339
pmcid: 3888714
Nor Hanipah Z, Nasr EC, Bucak E, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8. https://doi.org/10.1016/j.soard.2017.10.002 .
doi: 10.1016/j.soard.2017.10.002
pubmed: 29287757
Toth AT, Gomez G, Shukla AP, et al. Weight loss medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Children (Basel). 2018;5(9). https://doi.org/10.3390/children5090116 .
Das SR, Everett BM, Birtcher KK, et al. Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117–45. https://doi.org/10.1016/j.jacc.2020.05.037 .
doi: 10.1016/j.jacc.2020.05.037
pubmed: 32771263
pmcid: 7545583
Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC Guideline Comparison. J Am Coll Cardiol. 2022;79(18):1849–57. https://doi.org/10.1016/j.jacc.2022.02.046 .
doi: 10.1016/j.jacc.2022.02.046
pubmed: 35512864
Wang Y, Beydoun MA. The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6–28. https://doi.org/10.1093/epirev/mxm007 .
doi: 10.1093/epirev/mxm007
pubmed: 17510091
Lincoln KD, Nguyen AW. Race, Ethnicity, and age differences in social relationships and obesity: findings from the National Survey of American Life. J Aging Health. 2022;34(3):435–47. https://doi.org/10.1177/08982643221085900 .
doi: 10.1177/08982643221085900
pubmed: 35440226
Cheng YJ, Kanaya AM, Araneta MRG, et al. Prevalence of diabetes by race and ethnicity in the United States, 2011-2016. JAMA. 2019;322(24):2389–98. https://doi.org/10.1001/jama.2019.19365 .
doi: 10.1001/jama.2019.19365
pubmed: 31860047
pmcid: 6990660
He J, Zhu Z, Bundy JD, et al. Trends in cardiovascular risk factors in US adults by race and ethnicity and socioeconomic status, 1999-2018. JAMA. 2021;326(13):1286–98. https://doi.org/10.1001/jama.2021.15187 .
doi: 10.1001/jama.2021.15187
pubmed: 34609450
pmcid: 8493438
Abou Saleh M, Alkhayyat M, Mansoor E, et al. The risk of vitamin D deficiency, osteoporosis, and fractures in acute pancreatitis. Pancreas. 2020;49(5):629–33. https://doi.org/10.1097/MPA.0000000000001538 .
doi: 10.1097/MPA.0000000000001538
pubmed: 32433399
Kim EY. Definition, mechanisms and predictors of weight loss failure after bariatric surgery. J Metab Bariatr Surg. 2022;11(2):39–48. https://doi.org/10.17476/jmbs.2022.11.2.39 .
doi: 10.17476/jmbs.2022.11.2.39
pubmed: 36926678
Angrisani L, Ferraro L, Santonicola A, et al. Long-term results of laparoscopic Roux-en-Y gastric bypass for morbid obesity: 105 patients with minimum follow-up of 15 years. Surg Obes Relat Dis. 2021;17(4):727–36. https://doi.org/10.1016/j.soard.2020.11.028 .
doi: 10.1016/j.soard.2020.11.028
pubmed: 33390352
Grönroos S, Helmiö M, Juuti A, et al. Effect of laparoscopic sleeve gastrectomy vs roux-en-y gastric bypass on weight loss and quality of life at 7 years in patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2021;156(2):137–46. https://doi.org/10.1001/jamasurg.2020.5666 .
doi: 10.1001/jamasurg.2020.5666
pubmed: 33295955
Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity-trends using a population level national database. Obes Surg. 2021;31(3):1105–12. https://doi.org/10.1007/s11695-020-04987-2 .
doi: 10.1007/s11695-020-04987-2
pubmed: 32986169